1609 related articles for article (PubMed ID: 28109892)
1. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
2. Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach.
Serviddio G; Bellanti F; Villani R; Tamborra R; Zerbinati C; Blonda M; Ciacciarelli M; Poli G; Vendemiale G; Iuliano L
Redox Biol; 2016 Oct; 9():296-305. PubMed ID: 27639112
[TBL] [Abstract][Full Text] [Related]
3. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.
Bellanti F; Villani R; Tamborra R; Blonda M; Iannelli G; di Bello G; Facciorusso A; Poli G; Iuliano L; Avolio C; Vendemiale G; Serviddio G
Redox Biol; 2018 May; 15():86-96. PubMed ID: 29220698
[TBL] [Abstract][Full Text] [Related]
5. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
6. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
[TBL] [Abstract][Full Text] [Related]
7. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
8. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
9. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
Yan Z; Miao X; Zhang B; Xie J
Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
[TBL] [Abstract][Full Text] [Related]
10. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging.
Gong Z; Tas E; Yakar S; Muzumdar R
Mol Cell Endocrinol; 2017 Nov; 455():115-130. PubMed ID: 28017785
[TBL] [Abstract][Full Text] [Related]
11. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
12. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways of nonalcoholic fatty liver disease development and progression.
Bessone F; Razori MV; Roma MG
Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
16. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice.
Quesada-Vázquez S; Colom-Pellicer M; Navarro-Masip È; Aragonès G; Del Bas JM; Caimari A; Escoté X
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684533
[TBL] [Abstract][Full Text] [Related]
17. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
18. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
20. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
Akie TE; Liu L; Nam M; Lei S; Cooper MP
PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
